We serve Chemical Name:1-(4-isocyanatophenyl)pyrrole CAS:857283-60-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(4-isocyanatophenyl)pyrrole
CAS.NO:857283-60-4
Synonyms:1-(4-Isocyanatophenyl)-1H-pyrrole;4-pyrrolylbenzenisocyanate;1H-Pyrrole,1-(4-isocyanatophenyl)
Molecular Formula:C11H8N2O
Molecular Weight:184.19400
HS Code:2933990090
Physical and Chemical Properties:
Melting point:64.5-66.5ºC
Boiling point:291.4ºC at 760 mmHg
Density:1.11g/cm3
Index of Refraction:1.592
PSA:34.36000
Exact Mass:184.06400
LogP:2.44460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-(4-Isocyanatophenyl)-1H-pyrrole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Pyrrole,1-(4-isocyanatophenyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Pyrrole,1-(4-isocyanatophenyl) Use and application,4-pyrrolylbenzenisocyanate technical grade,usp/ep/jp grade.
Related News: An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug. 1-(4-isocyanatophenyl)pyrrole manufacturer Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. 1-(4-isocyanatophenyl)pyrrole supplier Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. 1-(4-isocyanatophenyl)pyrrole vendor The Environmental Working Group, a nonprofit advocacy organization, applauded the bill’s introduction. 1-(4-isocyanatophenyl)pyrrole factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.
